Personalized medicine—delivering therapies specially tailored to a patient’s unique physiology—has been a goal of researchers and doctors for a long time. New research provides a way of delivering personalized treatments to patients with neurological disease.
Researchers at the Montreal Neurological Institute and Hospital (The Neuro) of McGill University and the Ludmer Centre for Neuroinformatics and Mental Health have developed what they call a personalized Therapeutic Intervention Fingerprint (pTIF). The pTIF predicts the effectiveness of targeting specific biological factors (brain amyloid/tau deposition, inflammation, neuronal functional dysregulation) for controlling the evolution of the patient’s disease. Their results were published in the journal Neuroimage on June 14, 2018.
Lead by the study’s first author, Yasser Iturria-Medina, researchers used computational brain modeling and artificial intelligence techniques to analyze the neurological data from 331 Alzheimer’s patients and healthy controls. The data included multiple modes of positron emission tomography (PET) and magnetic resonance imaging (MRI). From this, Iturria-Medina and colleagues were able to categorize patients into their TIF subtypes, according to the potentially most beneficial factor-specific interventions.
The authors verified these subtypes were relevant by comparing them to the patients’ individual genetic profiles. They found patients in the same pTIF subtype had similar gene expression, meaning the mechanism in which genes affect their physiology is similar. Because drugs to control disease progression would have to modify gene expression and brain properties at the same time, drugs tailored to pTIF subtypes would be much more effective than drugs designed to treat all Alzheimer’s disease patients.
This is the first study to pinpoint a direct link between brain dynamics, predicted therapeutic responses, and molecular and cognitive alterations in patients. Using pTIF subtypes, drugs can be designed for a patient’s unique gene expression profile and phenotypic brain characteristics, which is a major advancement in personalized medicine. It could also improve the effectiveness and reduce the cost of clinical drug trials if used as a method to select patients.
Source: Read Full Article